Xbrane Biopharma AB (publ) has carried out a preferential rights issue of units of approximately SEK 337 million. 

Xbrane develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane is listed on Nasdaq Stockholm.

Pareto Securities acted as Sole Manager and Bookrunner. Baker McKenzie acted as legal advisor to Xbrane with a capital markets team consisting of Joakim Falkner, Stefan Balazs, Olof Larsson, Monica Ericson, Carl Bohman, Carl Isaksson and Simon Olofsson.
Explore Our Newsroom